Nocturia - Pipeline Review, H1 2017

Publisher Name :
Date: 28-Feb-2017
No. of pages: 33
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Pipeline Review, H1 2017, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape.

Nocturia is defined as need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women, sometimes for different reasons. Causes of nocturia include congestive heart failure, edema of lower extremities, sleeping disorders such as obstructive sleep apnea, certain drugs, including diuretics (water pills), cardiac glycosides, demeclocycline, lithium, methoxyflurane, phenytoin, propoxyphene, and excessive vitamin d and drinking too much fluid before bedtime, especially coffee, caffeinated beverages, or alcohol. Treatment includes anticholinergic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nocturia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nocturia (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 2 and 2 respectively.

Nocturia (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System And Sex Hormones).

  • The pipeline guide reviews pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Nocturia (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Nocturia (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Nocturia - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nocturia - Overview
Nocturia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nocturia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nocturia - Companies Involved in Therapeutics Development
Allergan Plc
Astellas Pharma Inc
Ferring International Center SA
Sanwa Kagaku Kenkyusho Co Ltd
Vantia Therapeutics
Nocturia - Drug Profiles
(acetaminophen + ibuprofen) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7398 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desmopressin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desmopressin acetate ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedovapagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nocturia - Dormant Projects
Nocturia - Product Development Milestones
Featured News & Press Releases
Oct 20, 2016: FDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray)
May 08, 2016: Studies Demonstrate New Options to Help Prevent and Treat Nocturia
May 03, 2016: Allergan Presents New Data on SER120 at the American Urological Association Meeting in San Diego
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Nocturia, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Nocturia - Pipeline by Allergan Plc, H1 2017
Nocturia - Pipeline by Astellas Pharma Inc, H1 2017
Nocturia - Pipeline by Ferring International Center SA, H1 2017
Nocturia - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017
Nocturia - Pipeline by Vantia Therapeutics, H1 2017
Nocturia - Dormant Projects, H1 2017

List of Figures

Number of Products under Development for Nocturia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Urinary Incontinence - Pipeline Review, H1 2017
    Published: 28-Feb-2017        Price: US 2000 Onwards        Pages: 66
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors includ......
  • Interstitial Cystitis (Painful Bladder Syndrome)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Interstitial Cystitis (Painful Bladder Syndrome)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Interstitial Cystitis (Painful Bladder Syndrome) Report is to understand the market and pipeline status of the drugs around the Interstitial Cystitis (Painful Bladder Syndrome) to explore th......
  • Interstitial Cystitis  - Epidemiology Forecast To 2023
    Published: 01-Jan-2017        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Interstitial Cystitis - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Interstitial Cystitis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Interstitial Cystitis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need ass......
  • Bladder Pain-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Bladder Pain-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Bladder Pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fun......
  • Interstitial Cystitis-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Interstitial Cystitis-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Interstitial Cystitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations,......
  • Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Interstitial Cystitis (Painful Bladder Syndrome). The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activ......
  • Urethritis-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Urinary Incontinence-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Nocturnal Enuresis - Epidemiology Forecast To 2023
    Published: 01-Jan-2017        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Nocturnal Enuresis - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Nocturnal Enuresis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Nocturnal Enuresis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs